购物车
- 全部删除
- 您的购物车当前为空
SCH 58261 是一种强选择性的竞争性腺苷 A2A 受体拮抗剂,IC50值为 15 nM,对 A2A 受体的选择性分别是 A1、A2B 和 A3 受体的 323 倍、53 倍、100 倍。
为众多的药物研发团队赋能,
让新药发现更简单!
SCH 58261 是一种强选择性的竞争性腺苷 A2A 受体拮抗剂,IC50值为 15 nM,对 A2A 受体的选择性分别是 A1、A2B 和 A3 受体的 323 倍、53 倍、100 倍。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 292 | 现货 | |
2 mg | ¥ 397 | 现货 | |
5 mg | ¥ 645 | 现货 | |
10 mg | ¥ 1,270 | 现货 | |
25 mg | ¥ 2,420 | 现货 | |
50 mg | ¥ 3,850 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 695 | 现货 |
产品描述 | SCH 58261 is a potent and selective A2a adenosine receptor antagonist.The Ki =2.3 nM for rat A2a and 2 nM is for bovine A2a. |
靶点活性 | A2A (rat):2.3 nM(Ki), A2a (bovine):2.0 nM(Ki) |
体外活性 | SCH 58261 causes the inhibition of rabbit platelet aggregation and porcine coronary artery relaxation by antagonizing competitively the effects induced by CGS 21680. [1] |
体内活性 | In mice with Spinal cord injury, SCH58261 (0.01 mg/kg, i.p.) reduces demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK MAPK. Chronic SCH58261 administration improves the neurological deficit up. [2] In rats with 6-OHDA-induced Parkinson's disease, SCH58261 (2 mg/kg, i.p.) improves the 6-OHDA-induced bradykinesia and motor disturbance. [3] |
别名 | SCH58261 |
分子量 | 345.36 |
分子式 | C18H15N7O |
CAS No. | 160098-96-4 |
Smiles | Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1 |
密度 | 1.54g/cm3 |
存储 | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 34.5 mg/mL (99.9 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
评论内容